
Opinion|Videos|May 14, 2024
Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps
The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bipartisan Legislation Introduced to Control Drug Prices, ‘Corporate Greed’ Within Health Care
2
FDA Approves Drug Labeling Changes to 6 Menopausal Hormone Therapy Products
3
Trispecific Antibody IBI3003 Receives Fast Track Designation for Relapsed or Refractory Multiple Myeloma
4
FDA Moves to Restrict Mass-Marketed Compounded GLP-1 Products
5









































